Interprofessional Insights for Managing Chronic Kidney Disease–associated Pruritus: Embracing Evolving Data and Emerging Agents to Optimize Outcomes
Nephrologists, cardiologists, and primary care physicians who help manage patients with cardiorenal anemia syndrome, including non–dialysis-dependent chronic kidney disease (NDD-CKD), heart failure (HF), or both.
• Review the prevalence of chronic kidney disease–associated pruritus (CKD-aP), especially in patients on dialysis, and identify the importance of symptom recognition and diagnosis.
• Describe the deleterious impact of CKD-aP on patient quality of life, sleep integrity, mental health, and overarching clinical outcomes.
• Examine the etiology and pathophysiology of CKD-aP, with an emphasis on opioid receptor dysregulation as a novel treatment target.
• Appraise completed, ongoing, and planned clinical trial data for CKD-aP therapies, including the recent FDA approval of difelikefalin.
• Use real-world patient cases to design evidence-supported and patient-centric strategies for CKD-aP symptom recognition, diagnosis, and treatment.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from Vifor Pharma.
5 minutes – Welcome and Introductions/Pre-Test
10 minutes – Foundations of Change: The Prevalence, Pathophysiology, and Patient-centric Clinical Gravity of CKD-aP
15 minutes – Novel Approaches, Novel Outcomes: A Review of the Evidence-supported Rationale for Targeting Opioid Receptor Pathways in CKD-aP Management.
20 minutes – Putting the Data to Work: Practical Principles for Improving CKD-aP Management in Today’s Hospital or Dialysis Clinic
10 minutes – Conversations with the Experts: Audience Q&A/Post-test
Steven Fishbane, MD
Long Island Jewish Medical Center
North Shore University
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Lisa Koester-Wiedemann, ANP, CNN-NP–has no relevant financial relationships to disclose in relation to the content of this activity.
Steven Fishbane, MD–has disclosed that he has received grants for clinical research and served as an advisor or consultant to Roche, Amgen, Watson, and Affymax. Dr. Fishbane has also disclosed that he has received grants for educational activities from Roche, Amgen, and Watson.
Katherine Lee, PharmD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Erin Spencer, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-23-001-L01-P)
This activity is designated for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 ICPE
- 1.00 Participation